Designing Viral Challenge Efficacy Studies That Stand Up to Scrutiny: A Practical Perspective from Southern Research

In preclinical development, few study types carry as much weight or risk as viral challenge studies. These experiments often serve as the proving ground where promising immunogenicity data must translate into real-world protection. When designed well, a challenge study can bring clarity and confidence to a program. When designed poorly, it can introduce ambiguity that lingers well into regulatory review.

The difference comes down to biological relevance, rigor, and intent. At Southern Research, challenge studies are not treated as standalone experiments, but as integrated decision-making tools that inform development strategy, regulatory positioning, and ultimately clinical readiness.

Building a Foundation That Reflects Real Disease

A successful challenge study begins long before animals are dosed. The foundational question is whether the chosen model is truly permissive to the virus being studied. If the virus cannot replicate appropriately or does not produce a disease that resembles human infection, even the cleanest data can be misleading.

Model selection must be intentional and biologically grounded. In some cases, that means incorporating both small and large animal species to ensure that the disease course, tissue tropism, and immune response align with what is seen clinically. The objective is not simply to generate an observable effect, but to establish a model that behaves in a way regulators and sponsors can trust.

During the COVID-19 pandemic, Southern Research collaborated with NIAID and BARDA to develop mild, moderate, and severe COVID-19 disease models in NHPs, Syrian hamsters, and ACE2-transgenic mice, respectively, to mimic the spectrum of disease severity observed in humans.

Defining Endpoints That Create Clarity, Not Confusion

Once the model is established, the study’s endpoints become the true drivers of insight. Endpoints determine whether protection is measurable, defensible, and meaningful. Survival, weight loss, fever, clinical signs, viral burden, and transmission-related markers each play a role, depending on the virus and disease state being modeled.

Overly mild models often require excessive interpretation, with sponsors spending months trying to tease apart small differences that are difficult to justify later. In contrast, models with clearer disease manifestation can accelerate decision-making and support confident advancement by allowing efficacy signals to emerge with far less ambiguity.

Matching the Model to the Scientific Question

Not all vaccine programs are asking the same question, and not all animal models are equipped to answer them. Some candidates aim to prevent infection entirely, while others are designed to reduce disease severity or limit transmission. Those distinctions matter deeply when selecting an animal model.

A model must be capable of reproducing the clinical features relevant to the study objective. If the biology of the model does not allow those features to manifest, critical signals may be missed or misinterpreted. At Southern Research, model selection is driven by the biology of the virus and the intent of the program, not by convenience or convention.

Relevance Matters More Than Severity

There is often a temptation to rely on lethal models because they offer clear, binary endpoints. However, lethality alone does not guarantee relevance. If death results from mechanisms that do not reflect how the virus causes disease in humans, the data may raise more questions than it answers. Antiviral challenge efficacy studies often require careful fine-tuning of the challenge dose to avoid overwhelming the models and obscuring small but meaningful efficacy signals.

Strong challenge studies mirror human infection as closely as possible. That includes the route of exposure, the tissues involved, the progression of disease, and the immune mechanisms driving pathology and protection. When these elements align, efficacy signals are not only easier to interpret but far more credible in regulatory discussions.

Using Challenge Studies to Define Correlates of Protection

Beyond efficacy, challenge studies are essential for defining correlates of protection. These correlates represent the threshold at which immune responses translate into measurable benefit, such as reduced viral replication or mitigated clinical symptoms.

Rather than relying on a single numerical cutoff, Southern Research evaluates ranges of immune activity and connects them directly to biological outcomes. This approach reflects the inherent variability of immune systems while still providing actionable insight. When correlates are supported by both immunogenicity data and challenge outcomes, they become powerful tools for regulatory strategy and program positioning.

Ready When Needed Vaccine Development

Southern Research’s ability to design high-impact challenge studies is rooted in preparedness. Decades of federally funded infectious disease work have shaped an infrastructure designed to respond quickly without sacrificing rigor. Viral repositories, pre-characterized assays, established animal models, and multidisciplinary scientific teams allow studies to move forward efficiently, even under compressed timelines.

For many vaccine developers, including virtual and AI-driven organizations, Southern Research serves as a translational bridge. The same experts who help design the study are directly involved in execution and interpretation, ensuring continuity, accountability, and scientific integrity throughout the process.

Shepherding Vaccine Candidates Toward the Clinic

Southern Research exists to shepherd test articles into the clinic. That philosophy shapes how challenge studies are approached: not as isolated experiments, but as pivotal moments in a vaccine’s journey.

By prioritizing biological relevance, clear endpoints, and integrated interpretation, Southern Research helps sponsors generate data that stands up to scrutiny and supports confident progression toward human trials. Because in this work, clarity is not just helpful. It is essential.